Progressive Supranuclear Palsy Pipeline Summary

DelveInsight’s, “Progressive Supranuclear Palsy - Pipeline Insight, 2026” report provides comprehensive insights about 10+ companies and 12+ pipeline drugs in Progressive Supranuclear Palsy pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Progressive Supranuclear Palsy: Understanding

Progressive Supranuclear Palsy: Overview

Progressive supranuclear palsy (PSP) is an uncommon, progressive neurodegenerative disorder and a form of atypical parkinsonism, also known as a Parkinson-plus syndrome. It affects multiple neurological functions, including movement, gait, balance, speech, swallowing, vision, eye movements, cognition, mood, and behavior. The classic clinical presentation is characterized by progressive axial rigidity, early postural instability and falls, supranuclear gaze abnormalities, pseudobulbar dysfunction, and cognitive impairment. Different clinical phenotypes of PSP exist depending on the brain regions predominantly affected and the extent of abnormal tau accumulation.

The exact cause of PSP remains unknown. The disease is generally considered sporadic, and increasing age is an important risk factor. Environmental factors, including possible exposure to toxins, have been proposed as contributing factors. Other hypotheses include the involvement of unconventional infectious agents, random genetic mutations, or exposure to unidentified chemicals in food, air, or water that may gradually damage vulnerable regions of the brain. However, none of these proposed factors has been established as a definitive cause of PSP.

The defining pathological feature of PSP is the abnormal accumulation of the microtubule-associated protein tau, particularly the four-repeat (4R) tau isoform, in specific regions of the brain. Tau aggregates form neurofibrillary tangles, oligodendrocytic coils, and astrocytic tufts, with prominent involvement of the subthalamic nucleus, pallidum, striatum, substantia nigra, red nucleus, pontine tegmentum, oculomotor nucleus, medulla, and dentate nucleus. Normally, tau stabilizes neuronal microtubules; however, in PSP, tau becomes hyperphosphorylated, reducing its ability to bind microtubules and making it more resistant to degradation. This promotes tau accumulation, neuronal dysfunction and progressive neurodegeneration, ultimately producing the characteristic motor, ocular, cognitive, and behavioral manifestations of PSP.

PSP is primarily diagnosed clinically because there is no single definitive test that can reliably diagnose the disease during life. The 2017 Movement Disorder Society (MDS) PSP criteria are used to evaluate characteristic clinical features, including vertical supranuclear gaze palsy or slowed vertical saccades, early postural instability and falls, axial rigidity, poor response to levodopa, early dysphagia or dysarthria, and characteristic cognitive or behavioral abnormalities. Brain MRI can support the diagnosis by demonstrating midbrain atrophy and other characteristic changes; the “hummingbird sign” caused by rostral midbrain atrophy is a recognized imaging feature. FDG-PET may demonstrate fronto-subcortical hypometabolism, while DaTscan can help distinguish PSP from some mimicking conditions, although it cannot reliably differentiate PSP from Parkinson’s disease.

There is currently no curative or established disease-modifying treatment for PSP, so management is primarily symptomatic and supportive. Levodopa combined with a dopa-decarboxylase inhibitor such as carbidopa may be tried for parkinsonian symptoms, although the response is generally modest or absent, with somewhat greater potential benefit in the PSP-parkinsonism phenotype. Amantadine may occasionally be considered, while botulinum toxin can be used for focal dystonia and eyelid-opening apraxia.

"Progressive Supranuclear Palsy- Pipeline Insight, 2026" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Progressive Supranuclear Palsy pipeline landscape is provided which includes the disease overview and Progressive Supranuclear Palsy treatment guidelines. The assessment part of the report embraces, in depth Progressive Supranuclear Palsy commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Progressive Supranuclear Palsy collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

• The companies and academics are working to assess challenges and seek opportunities that could influence Progressive Supranuclear Palsy R&D. The therapies under development are focused on novel approaches to treat/improve Progressive Supranuclear Palsy.

Progressive Supranuclear Palsy Emerging Drugs Chapters

This segment of the Progressive Supranuclear Palsy report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Progressive Supranuclear Palsy Emerging Drugs

• NIO752: Novartis AG

NIO752 is an investigational tau antisense oligonucleotide (ASO) developed by Novartis for the treatment of progressive supranuclear palsy (PSP). NIO752 is designed to target MAPT (microtubule-associated protein tau) mRNA, which encodes the tau protein, thereby reducing tau production. By lowering the amount of tau available for accumulation, NIO752 is intended to address the abnormal tau pathology underlying PSP and potentially slow disease progression. The drug is administered intrathecally to deliver the ASO into the cerebrospinal fluid and central nervous system. Currently, the drug is being evaluated in the Phase III stage of its development for the treatment of Progressive Supranuclear Palsy.

• AZP2006: Alzprotect

AZP2006 is an investigational, first-in-class orally available small-molecule drug designed to stabilize the progranulin (PGRN)–prosaposin (PSAP) complex, enhancing its trafficking to lysosomes and thereby restoring lysosomal function. According to Alzprotect, this mechanism increases PGRN availability, supports neuronal survival and neurite growth, reduces hyperphosphorylated Tau and misfolded protein accumulation, and attenuates neuroinflammation and oxidative stress. Through these multiple effects, AZP2006 is intended to address key pathological mechanisms involved in PSP rather than targeting Tau alone. Currently, the drug is being evaluated in the Phase II stage of its development for the treatment of Progressive Supranuclear Palsy.

• ARV-102: Arvinas

ARV-102 is an investigational, orally bioavailable PROTAC (proteolysis-targeting chimera) designed to cross the blood–brain barrier and selectively target leucine-rich repeat kinase 2 (LRRK2) for degradation. By recruiting the cell’s natural protein-degradation machinery, ARV-102 promotes the removal of LRRK2 rather than simply inhibiting its activity. Arvinas states that increased LRRK2 levels and activity are associated with impaired endolysosomal function and neuroinflammation and may contribute to abnormal protein accumulation, including tau pathology in PSP. Currently, the drug is being evaluated in the Phase I stage of its development for the treatment of Progressive Supranuclear Palsy.

Further product details are provided in the report……..

Progressive Supranuclear Palsy: Therapeutic Assessment

This segment of the report provides insights about the different Progressive Supranuclear Palsy drugs segregated based on following parameters that define the scope of the report, such as:

• Major Players in Progressive Supranuclear Palsy

There are approx. 10+ key companies which are developing the therapies Progressive Supranuclear Palsy. The companies which have their Progressive Supranuclear Palsy drug candidates in the most advanced stage, i.e. Phase III include, Novartis AG and others.

• Phases

DelveInsight’s report covers around 12+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

• Route of Administration

Progressive Supranuclear Palsy pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Intra-articular
• Intraocular
• Intrathecal
• Intravenous
• Ophthalmic
• Oral
• Parenteral
• Subcutaneous
• Topical
• Transdermal

• Molecule Type

Products have been categorized under various Molecule types such as

• Oligonucleotide
• Peptide
• Small molecule

• Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Progressive Supranuclear Palsy: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Progressive Supranuclear Palsy therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Progressive Supranuclear Palsy drugs.

Progressive Supranuclear Palsy Report Insights

• Progressive Supranuclear Palsy Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Progressive Supranuclear Palsy Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Progressive Supranuclear Palsy drugs?
• How many Progressive Supranuclear Palsy drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Progressive Supranuclear Palsy?
• What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Progressive Supranuclear Palsy therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Progressive Supranuclear Palsy and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Novartis AG
• Alzprotect
• Arvinas
• Oligomerix
• Transposon Therapeutics, Inc.
• Switch Therapeutics
• Ferrer Internacional S.A.
• GemVax & KAEL

Key Products

• NIO752
• AZP2006
• ARV-102
• OLX-07010
• TPN-101
• CASi-MAPT
• FNP-223
• GV1001